Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (31)	12/18/2001 5:43:38 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 123

SOURCE: Celltech Group plc Celltech and Genentech Settle Boss/Cabilly US Patent Interference SLOUGH, England, Dec. 18 /PRNewswire/ -- Celltech (NYSE: CLL - news) and Genentech have reached a settlement in the matter of the US Patent Office interference involving Celltech's ``Boss'' patent application and Genentech's ``Cabilly'' patent application, both of which relate to antibody manufacturing technology. The settlement was concluded as a result of a mediation process ordered by the US District Court of the Northern District of California. Arising from this process, the settlement comes into effect following the recent grant of the Cabilly patent by the US Patent Office and an Order of the Court to revoke and withdraw the Boss patent and grant and issue the Cabilly patent. By this settlement, Celltech will be compensated by Genentech in terms of income from sales of products which would otherwise have been covered by the Boss patent until its normal expiry date in 2006. Celltech has also secured rights to Genentech's Cabilly patent for its products. Website: celltechgroup.com Celltech Group plc (NYSE: CLL; LSE: CCH) is one of Europe's largest biopharmaceutical companies, with an extensive late stage development pipeline and a profitable cash-generative pharmaceutical business. Celltech also possesses drug discovery capabilities of exceptional strength, including a leading position in antibody engineering.